Julie Qingli Liu

US Patent:

8013007, Sep 6, 2011

Filed:

Feb 26, 2008

Appl. No.:

12/072501

Inventors:

Julie F. Liu - Lexington MA, US

Assignee:

Concert Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 31/404
C07D 209/04

US Classification:

514415, 548491

Abstract:

This invention relates to novel compounds that are dihydroindoles derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel dihydroindoles derivatives that are derivatives of silodosin. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an α-1A-adrenoreceptor antagonist, such as silodosin.

US Patent:

8084464, Dec 27, 2011

Filed:

Dec 18, 2008

Appl. No.:

12/338754

Inventors:

Julie Liu - Lexington MA, US

Assignee:

CoNCERT Pharmaceuticals, Inc. - Lexington MA

International Classification:

C07D 217/12
A61K 31/472

US Classification:

514307, 546146

Abstract:

This invention relates to novel tetrahydroisoquinoline derivatives, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a dual OX-1/OX-2 orexin antagonist.

US Patent:

8124646, Feb 28, 2012

Filed:

Jun 15, 2010

Appl. No.:

12/816295

Inventors:

Julie F. Liu - Lexington MA, US

Assignee:

Concert Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 31/4035
C07D 209/50
A61P 31/00
A61P 1/04
A61P 19/02
A61P 9/00
A61P 35/00
A61P 11/06

US Classification:

514417, 548481

Abstract:

This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.

US Patent:

8263601, Sep 11, 2012

Filed:

Sep 2, 2010

Appl. No.:

12/874783

Inventors:

Roger D. Tung - Lexington MA, US
Julie F. Liu - Lexington MA, US
Scott L. Harbeson - Cambridge MA, US

Assignee:

CoNCERT Pharmaceuticals, Inc. - Lexington MA

International Classification:

C07D 473/10
A61K 31/522
A61P 1/16
A61P 13/12
A61P 25/02
A61P 3/10
C07B 59/00

US Classification:

51426336, 544267

Abstract:

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. In particular, this invention relates to novel substituted xanthine derivatives that are derivatives of a pentoxifylline metabolite. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. The compounds of the invention are represented by one of the following structural formulas:.

US Patent:

8278460, Oct 2, 2012

Filed:

Oct 15, 2010

Appl. No.:

12/905835

Inventors:

Julie F. Liu - Lexington MA, US
Scott L. Harbeson - Cambridge MA, US

Assignee:

Concert Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 31/4184
C07D 235/08

US Classification:

5483044, 514394

Abstract:

This invention relates to novel substituted benzimidazoles and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound that modulates the GABAreceptor. This invention also provides novel intermediates for the preparation of the compounds of the invention, and salts thereof.

US Patent:

8349817, Jan 8, 2013

Filed:

Dec 22, 2009

Appl. No.:

12/644758

Inventors:

Rose A. Persichetti - Stow MA, US
Julie F. Liu - Lexington MA, US
Craig E. Masse - Cambridge MA, US
Scott L. Harbeson - Cambridge MA, US

Assignee:

CoNCERT Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 31/4709
A61K 31/4365
A61K 31/616
A61P 3/10
A61P 9/00
A61P 9/10
A61P 11/06
A61P 29/00
C07D 401/12

US Classification:

514161, 514301, 514312, 546158

Abstract:

This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.

US Patent:

8354557, Jan 15, 2013

Filed:

Jun 17, 2009

Appl. No.:

12/456507

Inventors:

Julie F. Liu - Lexington MA, US
Xuejun Tang - Ellicott City MD, US
Scott L. Harbeson - Cambridge MA, US
Craig E. Masse - Cambridge MA, US

Assignee:

Concert Pharmaceuticals, Inc. - Lexington MA

International Classification:

C07C 215/68

US Classification:

564443

Abstract:

The present invention is directed to a process for preparing a 2,26,6-d-morpholine derivative represented by Structural Formula (I):.

US Patent:

8357674, Jan 22, 2013

Filed:

Jun 29, 2012

Appl. No.:

13/538952

Inventors:

Julie F. Liu - Lexington MA, US
Rose A. Persichetti - Stow MA, US

Assignee:

CoNCERT Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 31/4709
A61K 31/616
A61P 3/10
A61P 9/00
A61P 3/04
A61P 7/02
A61P 1/04
A61P 11/06
A61P 15/00
A61P 9/10
C07D 401/12

US Classification:

514161, 514312, 514301, 546158

Abstract:

This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of an phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.